Remember when it was really uncommon to find the Food and Drug Administration disregarding the advice of its outside experts? For instance, Dendreon's
Fools, those days are over.
Johnson & Johnson
Johnson & Johnson's antibiotic joins Schering-Plough's
Doribax's rejection probably shouldn't have come as a huge surprise. The panel just barely recommended approval -- voting eight to five that it was safe and seven to six that it was effective. Also, the FDA has increasingly scrutinized antibiotics in the last few months, with Wyeth
The take-home message for investors is that you can no longer count on the headline "FDA Advisory Panel Recommends Approval of Your Favorite Drug" to guide your investment decisions. Investors need to dig a little deeper by reading the FDA's advisory-panel briefing documents to get better insight into what the agency is thinking. And even then, don't count on it.
Fool contributor Brian Orelli, Ph.D., doesn't invest in a lot of industries he doesn't understand. He doesn't own shares of any company mentioned in this article. J&J is an Income Investor recommendation. The Fool's disclosure policy understands more than it's letting on.
More from The Motley Fool
3 Dividend Stocks That Pay Out Over $8 Billion a Year
Can these huge companies keep the big dividend bucks flowing?
Johnson & Johnson Aims to Start 2018 Healthy
Investors have high hopes for the healthcare conglomerate.
Is Johnson & Johnson a Buy?
Is now a good time to invest in the healthcare titan's stock?